MetLife Investment Management’s Precision BioSciences DTIL Stock Holding History

MetLife Investment Management’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-635	Closed	-$141K	–	2742
2021 Q4	$141K	Buy	635 +230	+57%	+$64.2K	﹤0.01%	2271
2021 Q3	$140K	Sell	405 -218	-35%	-$73.9K	﹤0.01%	2283
2021 Q2	$234K	Buy	623 +336	+117%	+$101K	﹤0.01%	2053
2021 Q1	$89.1K	Sell	287 -423	-60%	-$148K	﹤0.01%	2257
2020 Q4	$178K	Sell	710 -197	-22%	-$48.3K	﹤0.01%	2038
2020 Q3	$168K	Hold	907	–	–	﹤0.01%	1962
2020 Q2	$227K	Buy	907 +332	+58%	+$72.7K	﹤0.01%	1833
2020 Q1	$104K	Hold	575	–	–	﹤0.01%	2053
2019 Q4	$240K	Buy	+575	New	+$181K	﹤0.01%	1883

Other funds holding DTIL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

MetLife Investment Management's DTIL Position: Q1 2022 in Review

MetLife Investment Management sold out of Precision BioSciences (DTIL) in Q1 2022, closing a stake of 635 shares — an estimated $141K sold.

MetLife Investment Management first reported a position in DTIL in Q4 2019 and held it in 9 quarters. The position peaked at $240K in Q4 2019. 152 funds tracked by Wall St. Rank hold DTIL as of Q1 2022.

MetLife Investment Management reported no remaining Precision BioSciences position as of Q1 2022 after selling out during the quarter.
MetLife Investment Management sold 635 Precision BioSciences shares in Q1 2022, an estimated $141K.
MetLife Investment Management first reported a position in Precision BioSciences in Q4 2019 and held it in 9 quarters.
MetLife Investment Management's Precision BioSciences position peaked at $240K in Q4 2019.
152 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2022.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.